Sort by:
Need a comprehensive medical report on "Boehringer Ingelheim"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7
- Registration Number
- NCT02254044
Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 17
- Registration Number
- NCT02253862
Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT02254070
Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy Volunteers
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 33
- Registration Number
- NCT02253901
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BEA 2180 BRDrug: PlaceboDevice: Respimat®
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 59
- Registration Number
- NCT02254122
Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BILR 355 - Treatment D (current tablet formulation)Drug: BILR 355 - Treatment A (current tablet formulation)Drug: BILR 355 - Treatment B (new tablet formulation)Drug: BILR 355 - Treatment E (new capsule formulation)Drug: BILR 355 - Treatment C (new capsule formulation)
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT02253940
Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult Volunteers
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT02253849
Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult Volunteers
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT02253875
Bioequivalence Study of Tipranavir Stored at Controlled Temperature Compared With Tipranavir Stored at Controlled Refrigerated Conditions, Orally Co-administered With Ritonavir in Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02253888
Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: EFVDrug: TPV/RTV - high doseDrug: TPV/RTV - low dose
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 68
- Registration Number
- NCT02253823